

References

Chapter 21

Key references/suggested reading are marked with an asterisk.*

- 1 Organisation for Economic Co-operation and Development. Health at a Glance 2011: OECD Indicators. Pharmaceutical expenditure. OECD Publishing. Available from: <http://www.oecd.org/els/health-systems/49105858.pdf> (last accessed 18 November 2015).
- 2 Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson LL. Enhancing the rational use of new medicines across European health care systems. *European Journal of Clinical Pharmacology*. 2008;**64**(12):1137–8.
- 3 Luo J, Oliveira MA, Ramos MB, Maia A, Osorio-de-Castro CGS. Antiretroviral drug expenditure, pricing and judicial demand: an analysis of federal procurement data in Brazil from 2004–2011. *BMC Public Health*. 2014;**14**:367.
- 4 Caires de Souza AL, de Assis Acurcio F, Guerra Junior AA, Rezende Macedo do Nascimento RC, Godman B, Diniz LM. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. *Applied Health Economics and Health Policy*. 2014;**12**(1):19–32.
- 5 Godman B, Wettermark B, van Woerkom M, Fraeyman J, Alvarez-Madrado S, Berg C, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. *Frontiers in Pharmacology*. 2014;**5**:106.
- 6 Kaplan W, Wirtz V, Mantel-Teeuwisse A, Stolk P, Duthley B, Laing R. Priority Medicines for Europe and the World 2013 Update. Available from: http://www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_Web.pdf?ua=1 (last accessed 18 November 2015). **Good report highlighting priority disease areas in Europe*.
- 7 Gorokhovich LE, Chalkidou K, Shankar R. Improving access to innovative medicines in emerging markets: evidence and diplomacy as alternatives to the unsustainable status quo. *Journal of Health Diplomacy*. 2013;**1**(1):1–19.
- 8 Godman B, Malmstrom RE, Diogene E, Gray A, Jayathissa S, Timoney A, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? *Expert Review of Clinical Pharmacology*. 2015;**8**(1):77–94.
- 9 Wagner AK, Graves AJ, Reiss SK, Lecates R, Zhang F, Ross-Degnan D. Access to care and medicines, burden of health care expenditures, and risk protection: results from the World Health Survey. *Health Policy*. 2011;**100**(2–3):151–8.
- 10 Van Minh H, Kim Phuong NT, Saksena P, James CD, Xu K. Financial burden of household out-of pocket health expenditure in Viet Nam: findings from the National Living Standard Survey 2002–2010. *Social Science & Medicine*. 2013;**96**:258–63.
- 11 Nguyen KT, Khuat OT, Ma S, Pham DC, Khuat GT, Ruger JP. Effect of health expenses on household capabilities and resource allocation in a rural commune in Vietnam. *PLoS ONE*. 2012;**7**(10):e47423.
- 12 Seiter A. A Practical Approach to Pharmaceutical Policy. Washington, DC, World Bank, 2010. Available from: <https://openknowledge.worldbank.org/bitstream/handle/10986/2468/552030PUB0Phar10Box349442B01PUBLIC1.pdf?sequence=4> (last accessed 18 November 2015).
- 13 Barber SL, Huang B, Santoso B, Laing R, Paris V, Wu C. The reform of the essential medicines system in China: a comprehensive approach to universal coverage. *Journal of Global Health*. 2013;**3**(1):010303.
- 14 World Health Organisation. Drug and Therapeutics Committees – A Practical Guide. Available from: <http://apps.who.int/medicinedocs/pdf/s4882e/s4882e.pdf> (last accessed 18 November 2015).

- 15 Vogler S, Zimmermann N, Leopold C, de Joncheere K. Pharmaceutical policies in European countries in response to the global financial crisis. *Southern Medicine Review*. 2011;**4**(2):69–79.
- 16 Leopold C, Mantel-Teeuwisse AK, Seyfang L, Vogler S, de Joncheere K, Laing RO, et al. Impact of external price referencing on medicine prices – a price comparison among 14 European countries. *Southern Medicine Review*. 2012;**5**(2):34–41.
- 17 Leopold C, Vogler S, Mantel-Teeuwisse AK, de Joncheere K, Leufkens HG, Laing R. Differences in external price referencing in Europe: a descriptive overview. *Health Policy*. 2012;**104**(1):50–60.
- 18 Simoens S. A review of generic medicine pricing in Europe. *Generics and Biosimilars Initiative Journal*. 2012;**1**(1):8–12.
- 19 Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. *Frontiers in Pharmacology*. 2010;**1**:141.
- 20 Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries – an overview. *Generics and Biosimilars Initiative Journal (GaBI Journal)*. 2012;**1**(2):93–100.
- 21 Dylst P, Vulto A, Simoens S. Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? *Health Policy*. 2011;**101**(2):146–52.
- 22 Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A. Discounts and rebates granted to public payers for medicines in European countries. *Southern Medicine Review*. 2012;**5**(1):38–46.
- 23 Woerkom M, Piepenbrink H, Godman B, Metz J, Campbell S, Bennie M, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. *Journal of Comparative Effectiveness Research*. 2012;**1**(6):527–38.
- 24 Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2012;**12**(1):125–30.
- 25 Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2009;**9**(1):65–83.
- 26 Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp FM. Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. *Applied Health Economics and Health Policy*. 2009;**7**(3):137–47. *Soft regulations paper giving the background to the 4Es.
- 27 Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2010;**10**(6):707–22.
- 28 Voncina L, Strizrep T, Godman B, Bennie M, Bishop I, Campbell S, et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2011;**11**(4):469–79.
- 29 Malmstrom RE, Godman BB, Diogene E, Baumgartel C, Bennie M, Bishop I, et al. Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. *Frontiers in Pharmacology*. 2013;**4**:39.
- 30 Moon JC, Godman B, Petzold M, Alvarez-Madrado S, Bennett K, Bishop I, et al. Different initiatives across Europe to enhance losartan utilization post generics: impact and implications. *Frontiers in Pharmacology*. 2014;**5**:219.
- 31 Godman B, Petzold M, Bennett K, Bennie M, Bucsics A, Finlayson AE, et al. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources?: Findings from across Europe and their implications. *BMC Medicine*. 2014;**12**(1):98. *CNC study showing that it is difficult for health authorities to instigate demand-side measures in order to enhance the preferential prescribing of generic atypical antipsychotics.
- 32 Garuoliene K, Alonderis T, Marcinkevicius M. Pharmaceutical policy and the effects of the economic crisis: Lithuania. *EuroHealth*. 2011;**17**:1–4.
- 33 Martin A, Godman B, Miranda J, Tilstone J, Saleem N, Olsson E, et al. Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications. *Journal of Comparative Effectiveness Research*. 2014;**3**(1):41–51.

- 34 Bjorkhem-Bergman L, Andersen-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. *European Journal of Clinical Pharmacology*. 2013;**69**(Suppl. 1):73–8.
- 35 Lima-Dellamora Eda C, Caetano R, Gustafsson LL, Godman BB, Patterson K, Osorio-de-Castro CGS. An analytical framework for assessing drug and therapeutics committee structure and work processes in tertiary brazilian hospitals. *Basic & Clinical Pharmacology & Toxicology*. 2014;**115**(3):268–76.
- 36 Hoffmann M. The right drug, but from whose perspective? A framework for analysing the structure and activities of drug and therapeutics committees. *European Journal of Clinical Pharmacology*. 2013;**69**(Suppl. 1):79–87.
- 37 Wettermark B. The intriguing future of pharmacoepidemiology. *European Journal of Clinical Pharmacology*. 2013;**69**(Suppl. 1):43–51. *Good review of potential drug utilization approaches, according to the availability of different datasets.
- 38 Grimshaw J, Campbell M, Eccles M, Steen N. Experimental and quasi-experimental designs for evaluating guideline implementation strategies. *Family Practice*. 2000;**17**(Suppl. 1):S11–16.
- 39 Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. *Journal of Clinical Pharmacy and Therapeutics*. 2002;**27**(4):299–309.
- 40 Zeng W, Zhen J, Feng M, Campbell SM, Finlayson AE, Godman B. Analysis of the influence of recent reforms in China: cardiovascular and cerebrovascular medicines as a case history to provide future direction. *Journal of Comparative Effectiveness Research*. 2014;**3**(4):371–86.
- 41 Cacace M, Ettelt S, Mays N, Nolte E. Assessing quality in cross-country comparisons of health systems and policies: towards a set of generic quality criteria. *Health Policy*. 2013;**112**(1–2):156–62. *Summary of necessary considerations for conducting robust CNC studies.
- 42 Markovic-Pekovic V, Skrbic R, Godman B, Gustafsson LL. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2012;**12**(5):661–71.
- 43 Kalaba M, Godman B, Vuksanovic A, Bennie M, Malmstrom RE. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history? *Journal of Comparative Effectiveness Research*. 2012;**1**(6):539–49.
- 44 Sabate M, Pacheco JF, Ballarin E, Ferrer P, Petri H, Hasford J, et al. A compilation of research working groups on drug utilisation across Europe. *BMC Research Notes*. 2014;**7**:143. *Compilation of drug utilization research group across Europe.
- 45 Kwon HY, Hong JM, Godman B, Yang BM. Price cuts and drug spending in South Korea: the case of antihyperlipidemic agents. *Health Policy*. 2013;**112**(3):217–26.
- 46 Kesselheim AS, Outterson K. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals. *Health Affairs (Project Hope)*. 2010;**29**(9):1689–96.
- 47 Sabuncu E, David J, Bernede-Bauduin C, Pepin S, Leroy M, Boelle PY, et al. Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002–2007. *PLoS Medicine*. 2009;**6**(6):e1000084.
- 48 Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. *Lancet*. 2005;**365**(9459):579–87.
- 49 Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. *British Medical Journal (Clinical Research Edition)*. 2010;**340**:c2096.
- 50 Barnett ML, Linder JA. Antibiotic prescribing for adults with acute bronchitis in the United States, 1996–2010. *Journal of the American Medical Association*. 2014;**311**(19):2020–2.
- 51 Velickovic-Radovanovic R, Stefanovic N, Damnjanovic I, Kocic B, Antic S, Dinic M, et al. Monitoring of antibiotic consumption and development of resistance by enterobacteria in a tertiary care hospital. *Journal of clinical pharmacy and therapeutics*. 2015;**40**(4):426–30.
- 52 Godman B, Houng V, Binh H, Thai C, Gustafsson LL. Role of DTCs in Vietnam: current situation and implications for the future. *Basic & Clinical Pharmacology & Toxicology*. 2014;**115**(Suppl. 1):86.
- 53 Godman B, Huong V, Binh N, Gustafsson LL. Current activities of DTCs in Vietnam in drug selection and development of hospital formularies. *Basic & Clinical Pharmacology & Toxicology*. 2014;**115**(Suppl. 1):65.

- 54 Hassali MA, Alrasheedy AA, McLachlan A, Nguyen TA, Al-Tamimi SK, Ibrahim MI, et al. The experiences of implementing generic medicine policy in eight countries: a review and recommendations for a successful promotion of generic medicine use. *Saudi Pharmaceutical Journal*. 2014;**22**(6):491–503.
- 55 Hassali MA, Wong ZY, Alrasheedy AA, Saleem F, Mohamad Yahaya AH, Aljadhey H. Perspectives of physicians practicing in low and middle income countries towards generic medicines: a narrative review. *Health Policy*. 2014;**117**(3):297–310.
- 56 Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. *Journal of the American Medical Association*. 2008;**300**(21):2514–26.
- 57 Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. *Drugs*. 2010;**70**(5):605–21.
- 58 Corrao G, Soranna D, Merlino L, Mancina G. Similarity between generic and brand-name antihypertensive drugs for primary prevention of cardiovascular disease: evidence from a large population-based study. *European Journal of Clinical Investigation*. 2014;**44**(10):933–9.
- 59 Paton C. Generic clozapine: outcomes after switching formulations. *The British journal of psychiatry: the journal of mental science*. 2006;**189**:184–5.
- 60 World Health Organization. WHO Guideline on Country Pharmaceutical Pricing Policies. Available from: http://www.who.int/medicines/publications/pharm_guide_country_price_policy/en/ (last accessed 18 November 2015).
- 61 Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU. *Economic Papers* 461. Available from: http://ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdf (last accessed 18 November 2015).
- 62 Heinze G, Hronsky M, Reichardt B, Baumgartel C, Mullner M, Bucsics A, et al. Potential Savings in Prescription Drug Costs for Hypertension, Hyperlipidemia, and Diabetes Mellitus by Equivalent Drug Substitution in Austria: A Nationwide Cohort Study. *Applied Health Economics and Health Policy*. 2015;**13**(2):193–205.
- 63 Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. *Archives of Internal Medicine*. 2006;**166**(3):332–7.
- 64 Barbui C, Conti V. Adherence to generic v. brand antidepressant treatment and the key role of health system factors. *Epidemiology and Psychiatric Sciences*. 2015;**24**(1):23–6.
- 65 Kaplan WA, Ritz LS, Vitello M, Wirtz VJ. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000–2010. *Health Policy*. 2012;**106**(3):211–24.
- 66 Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. *Applied Health Economics and Health Policy*. 2010;**8**(1):7–24.
- 67 Andersson K, Sonesson C, Petzold M, Carlsten A, Lonnroth K. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. *Pharmacoepidemiology and Drug Safety*. 2005;**14**(5):341–8.
- 68 Godman B, Bishop I, Finlayson AE, Campbell S, Kwon HY, Bennie M. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2013;**13**(4):469–82.
- 69 Duerden MG, Hughes DA. Generic and therapeutic substitutions in the UK: are they a good thing? *British Journal of Clinical Pharmacology*. 2010;**70**(3):335–41.
- 70 Andersson KA, Petzold MG, Allebeck P, Carlsten A. Influence of mandatory generic substitution on pharmaceutical sales patterns: a national study over five years. *BMC Health Services Research*. 2008;**8**:50. *Good analysis of the impact of compulsory generic substitution in Sweden.
- 71 Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. *Journal of Clinical Pharmacy and Therapeutics*. 2010;**35**(2):139–51.
- 72 Martikainen JE, Saastamoinen LK, Korhonen MJ, Enlund H, Helin-Salmivaara A. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. *Medical Care*. 2010;**48**(9):761–6.

- 73 Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. *International Journal of Clinical Practice*. 2008;**62**(3):480–4.
- 74 Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs. *Pharmacoeconomics*. 2009;**27**(5):435–8.
- 75 Norman C, Zarrinkoub R, Hasselstrom J, Godman B, Granath F, Wettermark B. Potential savings without compromising the quality of care. *International Journal of Clinical Practice*. 2009;**63**(9):1320–6.
- 76 Sakshaug S, Furu K, Karlstad O, Ronning M, Skurtveit S. Switching statins in Norway after new reimbursement policy: a nationwide prescription study. *British Journal of Clinical Pharmacology*. 2007;**64**(4):476–81.
- 77 Hesse U, Godman B, Petzold M, Martin A, Malmstrom RE. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries. *Applied Health Economics and Health Policy*. 2013;**11**(6):677–85.
- 78 Godman B, Wettermark B, Miranda J, Bennie M, Martin A, Malmstrom RE. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries. *International Journal of Clinical Practice*. 2013;**67**(9):853–62.
- 79 Bennie M, Bishop I, Godman B, Campbell S, Miranda J, Finlayson AE, et al. Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland? *Quality in Primary Care*. 2013;**21**(1):7–15.
- 80 Parks J, Radke A, Parker G, Foti ME, Eilers R, Diamond M, et al. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. *Schizophrenia Bulletin*. 2009;**35**(5):931–6.
- 81 Wettermark B, Godman B, Neovius M, Hedberg N, Mellgren TO, Kahan T. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. *Health Policy*. 2010;**94**(3):221–9.
- 82 Gustafsson LL, Wettermark B, Godman B, Andersen-Karlsson E, Bergman U, Hasselstrom J, et al. The ‘wise list’ – a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. *Basic & Clinical Pharmacology & Toxicology*. 2011;**108**(4):224–33.
- 83 Niquille A, Ruggli M, Buchmann M, Jordan D, Bugnon O. The nine-year sustained cost-containment impact of swiss pilot physicians-pharmacists quality circles. *Annals of Pharmacotherapy*. 2010;**44**(4):650–7.
- 84 Wensing M, Broge B, Riens B, Kaufmann-Kolle P, Akkermans R, Grol R, et al. Quality circles to improve prescribing of primary care physicians: three comparative studies. *Pharmacoepidemiology and Drug Safety*. 2009;**18**(9):763–9.
- 85 Doran T, Kontopantelis E, Valderas JM, Campbell S, Roland M, Salisbury C, et al. Effect of financial incentives on incentivised and non-incentivised clinical activities: longitudinal analysis of data from the UK Quality and Outcomes Framework. *British Medical Journal*. 2011;**342**:d3590.
- 86 Wettermark B, Pehrsson A, Juhasz-Haverinen M, Veg A, Edlert M, Tornwall-Bergendahl G, et al. Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care. *Quality in Primary Care*. 2009;**17**(3):179–89.
- 87 Godman B, Abuelkhair M, Vitry A, Abdu S, Bennie M, Bishop I et al. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. *Generics and Biosimilars Initiative Journal*. 2012;**1**(2):21–35.
- 88 Pettersson B, Hoffmann M, Wandell P, Levin LA. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. *Health Policy*. 2012;**104**(1):84–91.
- 89 Little P, Stuart B, Francis N, Douglas E, Tonkin-Crine S, Anthierens S, et al. Effects of internet-based training on antibiotic prescribing rates for acute respiratory-tract infections: a multinational, cluster, randomised, factorial, controlled trial. *Lancet*. 2013;**382**(9899):1175–82.
- 90 Cals JW, Butler CC, Hopstaken RM, Hood K, Dinant GJ. Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. *British Medical Journal*. 2009;**338**:b1374.

- 91 Goossens H, Coenen S, Costers M, De Corte S, De Sutter A, Gordts B, et al. Achievements of the Belgian Antibiotic Policy Coordination Committee (BAPCOC). *Euro Surveillance*. 2008;**13**(46).
- 92 Formoso G, Paltrinieri B, Marata AM, Gagliotti C, Pan A, Moro ML, et al. Feasibility and effectiveness of a low cost campaign on antibiotic prescribing in Italy: community level, controlled, non-randomised trial. *British Medical Journal*. 2013;**347**:f5391.
- 93 Furst J, Cizman M, Mrak J, Kos D, Campbell S, Coenen S, et al. The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: findings and implications. *Expert Review of Anti-infective Therapy*. 2015;**13**(2):279–89.